



Opportunities for Collaborative Research in the Health theme of FP7

Stéphane Hogan

Head of unit – Horizontal Aspects and Coordination

Directorate Health

DG Research – European Commission



EUROPEAN
COMMISSION

Community research

Main points

- ∅ The 7th Framework programme (FP7)
 - ∅ Basic principles
 - ∅ Next calls (2008-2009)
 - ∅ Structure and content
 - ∅ SMEs and International collaboration
 - ∅ Results of first calls (2007-2008)



EUROPEAN
COMMISSION

Community research

Basic principles for calls and evaluations

- ∅ annual calls – competition – peer review
- ∅ 3 criteria:
 - ∅ Science & Technology excellence
 - ∅ Implementation & Management
 - ∅ Potential Impact
- ∅ evaluation by panels of independent experts
- ∅ overseen by Independent Observers



EUROPEAN
COMMISSION

Community research

Funding schemes in the Health theme

Main funding schemes: ceilings for EC & min. n° partners

∅ Large-scale integrating project (IP)	€12m	3
∅ Network of Excellence (NoE)	€5m or €12m	3
∅ Small- or medium-scale focussed research project (FP)	€3m or €6m	3
∅ Coordination action (CA)	€1m or €2m	1
∅ Support action (SA)	€0.5m or €1m	1

Warning: this is an eligibility criteria !





Next calls for proposals for the Health theme

- Ø IMI call to be published April 2008 (2008 budget)
 - Ø expected budget: €125 million
 - Ø deadline: July for EoI, October for full proposal (tbc)
 - Ø for information: www.imi.europa.eu

- Ø 3rd call to be published July 2008 (2009 budget)
 - Ø expected budget: €600 million
 - Ø expected deadline: Oct./Nov. 2008

- Ø 4th call published July 2009 (2010 budget)
 - Ø expected budget: € 600 million
 - Ø deadline: Oct./Nov. 2009



EUROPEAN
COMMISSION


Community research

Next call for proposals for the Health theme

- Ø 3rd call to be published July 2008 (2009 budget)
- Ø a draft work programme should be available April/May.
- Ø Two-stage submission/evaluation for parts of programme
- Ø expected deadlines
 - Ø Nov. 2008 for full proposals (for single-stage call)
 - Ø Oct. 2008 for 1st stage (Feb./March for 2nd stage)



the Health theme





the Health theme

1: Biotechnology, generic tools and technologies

∅ High-throughput research

enhancing data generation, standardisation, acquisition & analysis

∅ Detection, diagnosis and monitoring

with emphasis on non-invasive or minimally invasive approaches

∅ Predicting suitability, safety and efficacy of therapies

develop and validate parameters, tools, methods and standards (mainly through IMI) and alternatives to animal testing

∅ Innovative therapeutic approaches and interventions

gene and cell therapy, regenerative medicine, immunotherapy and vaccines.



2: Translating research for human health

- ∅ Integrating biological data and processes:
large-scale data gathering, systems biology
- ∅ Research on the brain and related diseases,
human development and ageing
- ∅ Translational research in major infectious diseases
to confront major threats to public health
antimicrobial drug resistance, HIV/AIDS, malaria and TB,
emerging epidemics, neglected infectious diseases
- ∅ Translational research in other major diseases:
cancer, cardiovascular disease, diabetes and obesity,
rare diseases, and other chronic diseases



the Health theme

3: Optimising the delivery of health care to citizens

- ∅ Translating clinical research into clinical practice
patient safety, better use of medicines, pharmacovigilance, etc.
- ∅ Quality, efficiency and solidarity of health care systems
organisational and financial aspects, health systems, etc.
- ∅ Enhanced health promotion and disease prevention
providing evidence of best public health measures – life styles,
interventions, special focus on mental health, etc.

4: Other actions across the theme

- ∅ Coordination and Support Actions across the Theme
- ∅ Responding to EU policy needs



SMEs participation & International Cooperation

Renewed emphasis and new measures for:

- ∅ Small and medium-sized enterprises (SMEs)
 - ∅ Participation encouraged in all areas
 - ∅ Special topics for SMEs
 - ∅ Support actions
 - ∅ more favourable conditions (75% of costs covered)
- ∅ International Cooperation
 - ∅ Participation possible in all areas
 - ∅ Special International Cooperation Actions (SICA)
 - ∅ Coordination or Support actions
 - ∅ new mechanisms: coordinated programmes and topics



More attractive conditions for research-intensive SMEs

- Medium/long term vision: 7-year programme
- Policy target: 15% of budget for SMEs = >€900m in Health
- Improved conditions in FP7
 - Strong support: up to 75% of total R&D costs and up to 100% for management & training
 - Better protection: IPR rules adapted to SMEs needs
 - Administrative simplification: reduced need for financial checks and bank guarantees



EUROPEAN
COMMISSION

Community research

Key figures from 1st calls in FP7 Health theme

Ø call: 2007-A (19 April 2007)

- Ø budget: € 635 million (2007)
- Ø proposals received: 914
- Ø proposals evaluated: 893 (ineligible 21)
- Ø proposals to be funded: 152
(= of proposals evaluated): 17%

call 2007-B (18 Sept. 2007)

- € 567 million (2008)
- 902
- 865 (37)
- 167
19%

Ø av. grant per participant: €412,000 €334,000

Ø SMEs in 120/152 projects (79%) 128/167 (77%)

Ø 299 SMEs involved (19%) 353 (20%)

Ø SMEs to receive: ~€100 million ~€108 million

= ~17% of budget





EUROPEAN
COMMISSION

Community research

Special SME call in FP6 "Health" theme

The SME-STREP call has been a major success in mobilising high-tech SMEs participation in EU-funded projects.

Ø call: 2007-A (19 April 2007)

Ø budget (2006) : € 171 million => raised to €200 million

Ø proposals funded: 86 projects

Ø 276 SMEs participants (40%)

Ø ~€ 94 million of budget went to SMEs (43%)

Ø average budget per SME: € 342,000

Ø 40/86 projects (46%) coordinated by SMEs

Ø >90% of SMEs are research-intensive

Ø 84 participants are French

Ø 3 projects coordinated by French SMEs





EUROPEAN
COMMISSION

Community research

QUACSIG coordinated by Genewave

Quantitative analysis of genes in single cells

"to develop methods and instruments for providing early diagnosis systems for a child disease, hemophagocitic lymphocytosis plus prenatal and postnatal diagnosis of trisomy 21"

- EC contribution: €1.5m over 2 years
- Coordinator is a SME: Genewave SA (FR)
- 5 participants including 3 SMEs
- SMEs play key scientific roles: development of automated cell picker; use of photolithographically structured microscope slide Ampligridd™; production of integrated system for PCR and optical detection of hybridization.





EUROPEAN
COMMISSION

Community research

POC4LIFE coordinated by Cezanne SA

Multi-parametric quantum dot bioassay for point-of-care diagnosis

"To provide clinicians with multi-parametric measurement of the 4/5 essential markers and support decision-making with a software tool."

- EC contribution: €2.5m over 3 years è 44% to SMEs
- Coordinator is a SME: Cezanne SA (FR)
- 9 participants, incl. 3 SMEs and 2 FR academic partners
- SMEs play key scientific roles: development of photonic and electro-optics; immunoassay development; production of monoclonal antibodies and recombinant proteins.





EUROPEAN
COMMISSION

Community research

MEGATOOLS coordinated by Collectis SA

New tools for functional genomics based on homologous recombination induced by double-strand break & specific meganucleases

"To develop new sequence-specific endonucleases to recognise & target any possible DNA sequence and optimise homologous recombination to provide scientists with powerful tool for functional genomics."

- EC contrib.: €2.0m over 3 years
- Coordinator is a SME, Collectis SA (FR)
- 4 participants including 2 SMEs
- SMEs play key scientific roles: providing genomic engineering, gene therapy and genome modification tools; expertise for discovery, manufacturing and marketing quality molecular biologicals.





Key factors for success in FP7

Competition is tough:
only the best projects get funded

- ∅ The proposal must be in scope with the topic and the work programme (not wishful thinking)
- ∅ The consortium of partners must be excellent and appropriate for the task (select the right partners)
- ∅ The proposal must address all 3 criteria
- ∅ Convince the evaluators (don't rely on reputation)
- ∅ and, of course, respect the basic rules (deadlines, n° participants, ceilings, length, ethics, ...)



EUROPEAN
COMMISSION

Community research

Contacts & Information

Consult the web page for **Health**:

<http://cordis.europa.eu/fp7/health>

including NCPs, Ethics, registration as an Expert

SME participation: Dr. Ludovica Serafini, DG Research

Tel. +32 2 295 6759 – Email: ludovica.serafini@ec.europa.eu

NCP for Health: Dr. Philippe Arhets, INSERM

Tel: 01 44 23 81 90 – Email: philippe.arhets@inserm.fr

NCP for SMEs: Michel Ganoote, OSEO

Tel: 01 41 79 93 31 – Email: michel.ganoote@oseo.fr

SMEsgoHealth: www.smesgohealth.org

EuroTransbio: www.eurotransbio.net





The Health Directorate

Director (acting) – Dr. Manuel Hallen:

Medical and Public Health Research unit (F2)

Head of unit: Dr. Manuel Hallen (manuel.hallen@ec.europa.eu)

Deputy Head of Unit: Dr. Maria Vidal (maria-jose.vidal-ragout@ec.europa.eu)

Head of sector Public Health: K. McCarthy (kevin.mccarthy@ec.europa.eu)

Infectious Diseases unit (F3)

Head of unit: Dr. Alain Vanvossel (alain.vanvossel@ec.europa.eu)

Deputy Head of unit: Dr. Anna Lönnroth (anna.lonnroth@ec.europa.eu)

Head of IMI sector: Dr. Irene Norstedt (irene.norstedt@ec.europa.eu)

Genomics and Systems Biology unit (F4)

Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu)

Deputy Head of unit: Dr. B. Mulligan (bernard.mulligan@ec.europa.eu)

Health Biotechnology unit (F5)

Head of unit: Dr. Arnd Hoeveler (arnd.hoeveler@ec.europa.eu)

Coordination unit (F1)

Head of unit: Stéphane Hogan

(stephane.hogan@ec.europa.eu)

Admin. & Finance unit (F6)

Head of unit: Giorgios Zisimatos

(giorgios.zisimatos@ec.europa.eu)